Energy & Endurance
MOTS-c
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Mitochondrial Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 40 mg
Dosing window: Pre-Workout
Receptor / target: AMPK
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 5mg 1x weekly | Inject subcutaneously 30-45 minutes pre-workout. |
| Weeks 5-8 | 5mg 2x weekly | Split doses evenly (e.g., Monday/Thursday) pre-workout. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Endurance Athletes
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 10mg 1x weekly | High-dose protocol utilized leading up to extreme endurance events. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 200 mcg | Inject once daily subcutaneously. |
| Weeks 3-4 | 400 mcg | Inject once daily subcutaneously. |
| Weeks 5-6 | 600 mcg | Inject once daily subcutaneously. |
| Weeks 7-8 | 800 mcg | Inject once daily subcutaneously. |
| Weeks 9-10+ | 1,000 mcg | Inject once daily subcutaneously. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3
| Timeframe | Dose | Notes |
|---|---|---|
| 40-80 days | 5 mg 1x Daily every 5 days |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4
| Timeframe | Dose | Notes |
|---|---|---|
| 8-10 weeks | 3 mg 1x Daily every 3 days |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (AMPK); route Subcutaneous; timing Pre-Workout. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.
Independent evidence
Independent safety notes: FDA lists MOTs-C among withdrawn nominated bulk substances with no identified human exposure data and insufficient safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Severe cardiovascular disease or unstable cardiac conditions: MOTS-c's AMPK activation drives an intense metabolic demand similar to vigorous exercise; subjects unable to tolerate the cardiovascular load of physical exertion should not use MOTS-c. Limited / unverified
- Active malignancy: AMPK pathway activation has complex effects on cancer cell metabolism; MOTS-c's nuclear translocation and gene regulatory activity in cancer cells is not characterized; use in active cancer is not established. Limited / unverified
- Insulin therapy or sulfonylurea use without clinical supervision: MOTS-c activates GLUT4 expression and increases muscle glucose uptake via AMPK, which combined with exogenous insulin or insulin secretagogues creates a meaningful additive hypoglycemia risk. Limited / unverified
- Metformin use: metformin also activates AMPK (through complex I inhibition); overlapping AMPK stimulation effects are not characterized; monitor blood glucose closely if combining. Limited / unverified
- Beta-blocker therapy: beta-blockers mask the adrenergic warning signs (tachycardia, tremor) of hypoglycemia; in conjunction with MOTS-c's glucose-lowering AMPK activity, this is a meaningful safety concern. Limited / unverified
- Pregnancy: MOTS-c modulates mitochondrial gene expression; safety during fetal development is entirely unknown. Limited / unverified
- Breastfeeding: no data. Limited / unverified
- Pediatric use: no safety or developmental data established. Limited / unverified
- Known hypersensitivity to MOTS-c or peptide excipients. Limited / unverified
- Athletes competing under WADA anti-doping regulations: MOTS-c is on the WADA Prohibited List. Limited / unverified
Side effects (limited evidence)
- Hypoglycemia when dosed fasted without exercise: the most practically significant adverse effect; AMPK activation drives aggressive glucose uptake and fatty acid oxidation in muscle; without the energy demand of physical activity, blood glucose can drop significantly; always dose pre-workout, never fasted without planned exercise. Limited / unverified
- Injection site reactions: redness, soreness, itching at subcutaneous site; the most commonly reported adverse effect in research and anecdotal use. Limited / unverified
- Transient fatigue and flu-like symptoms in the first days of use: as the metabolic programs are initially activated; typically resolves within the first week. Limited / unverified
- Mild flushing: sensation of warmth; related to increased metabolic rate and peripheral vasodilation from improved tissue perfusion. Limited / unverified
- Gastrointestinal disturbances: mild nausea, diarrhea reported in a small subset of research subjects; usually early-cycle. Limited / unverified
- Headache: mild; uncommon; mechanism not characterized. Limited / unverified
- Potential AMPK overstimulation: theoretical; excessive AMPK activation suppresses mTOR signaling, which while broadly pro-longevity, may impair muscle protein synthesis recovery after intense training if MOTS-c is dosed immediately post-workout. Limited / unverified
- No hormonal side effects: MOTS-c has no known activity at androgen, estrogen, or GH axis receptors. Limited / unverified
- Injection site infection risk from non-sterile research chemical sourcing: an acknowledged risk with all unregulated research peptides; sterile technique is paramount. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
5-Amino-1MQSS-31 (Elamipretide)HumaninNAD+AICARL-Carnitine (Injectable)SLU-PP-332Erythropoietin (EPO)
Reported contraindicated combinations:
None listed.